By Colin Kellaher
Biora Therapeutics has filed for chapter 11 bankruptcy with a deal in hand to be acquired by some of its lenders.
Biora on Monday said the lenders have agreed to provide up to $10.25 million in debtor-in-possession financing and serve as the stalking horse, or lead, bidder in a court-supervised auction of the San Diego clinical-stage biotech company's assets.
Biora said the funding will help it meet its obligations during the chapter 11 case, adding that it expects to operate its business as usual during the sale process.
Biora shares closed Friday at 44 cents, giving the company a market capitalization of just under $2 million.
Shareholders are generally wiped out in bankruptcy cases, and Biora warned that it expects its security holders will experience a significant or complete loss on their investment.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 30, 2024 08:17 ET (13:17 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。